Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD)

Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent, for the treatment of subjects with Alzheimer's disease.

Timeline

Start

2021-01-06

Primary completion

2023-08-16

Completion

2024-01-31

Publications

• Zuniga CH, Acosta BI, Menchaca R, Amescua CA, Hong S, Hui L, Gil M, Rhee YH, Yoon S, Kim M, Chang PY, Kim YM, Song PY, Betito K. Treatment of Alzheimer's Disease subjects with expanded non-genetically modified autologous natural killer cells (SNK01): a phase I study. Alzheimers Res Ther. 2025 Feb 12;17(1):40. doi: 10.1186/s13195-025-01681-2.

Drugs

Indications